Compare Enveric Biosciences Inc (ENVB) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wayfair Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Wayfair Inc trades at $104.47 (market cap $14.40B). The key difference: Wayfair Inc is far larger — about 2117.6× Enveric Biosciences Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Wayfair Inc for 8 Days on average.
| ENVB | W | |
|---|---|---|
Market Cap | $6.80M | $14.40B |
Volume | 64,867 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $119.05 |
52-Week Low | $1.27 | $57.40 |
Typical Hold Time | 14 Days | 8 Days |
Enterprise Value | -$1.49M | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Wayfair (W) trades at $104.47, down 0.93% on the day, showing mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company reported $12.46B revenue for 2025 but posted a net loss of $313M, with negative profit margins. Recent earnings show volatility, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Analyst sentiment remains positive with a 54% buy rating and $114.13 consensus price target, while the company expands physically with new store openings.
The outlook for Wayfair hinges on improving profitability amid ongoing losses. Near-term catalysts include Q3 2026 earnings on November 4, 2026, where meeting the $0.785 EPS estimate could boost sentiment. Risks include high debt-to-asset ratio of 95.11% and competitive pressures in online retail. The stock offers 9.2% upside to the consensus target, but investors should monitor cash flow trends after 2026's negative net cash flow of $261M.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
